Table 1. Effects of ZD4190 on the outgrowth of tumour in a muscle model of residual squamous cell carcinoma after 21 days of administration postoperatively.
|
Rectus
|
Gastrocnemius
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2 × 104
|
5 × 104
|
2 × 104
|
5 × 104
|
|||||||||
| ZD4190 | C | V | ZD4190 | C | V | ZD4190 | C | V | ZD4190 | C | V | |
| Fibrotic foci no tumour | 14 | 0 | 0 | 14 | 0 | 0 | 7 | 0 | 0 | 4 | 0 | 0 |
| Fibrotic foci Brdu−tumour | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
| Fibrotic foci Brdu+tumour | 3 | 0 | 0 | 4 | 0 | 4 | 1 | 0 | 0 | 2 | 0 | 0 |
| Brdu+tumour | 0 | 19 | 20 | 0 | 23 | 19 | 0 | 9 | 8 | 0 | 8 | 9 |
Different numbers of PDVC57B cells (2 × 104 and 5 × 104) were implanted to create each tumour tract in the rectus and gastrocnemius muscles and the mice (n=5) gavaged daily with ZD4190, vehicle (V) or were untreated (C). The different patterns of tumour outgrowth were assessed by morphological examination and BrdU staining. The number of fibrotic foci forming for each group of rodents and the pattern of Brdu expression is shown. A maximum number of five tracts were implanted into each rectus muscle and two into the gastrocnemius. Significantly more fibrotic foci formed in the rectus muscle (P=0.001, χ2 38) and the gastrocnemius (P=0.001, χ2 73.7) when treatments with ZD4190 and the controls or vehicle-treated groups were compared.